Payment overview · 2025
General Payments
$194.69
4 reported records · 4 companies
Healthcare provider profile · identity verified
Katlin Spillman, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GLASGOW, KY · NPI 1851802367
Verified facts
What the public records show
CMS Open Payments records show Katlin Spillman, APRN received $194.69 in general payments during 2025 across 4 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 66.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $129.36 | 66.4% | 1 | 2025 |
| Calyxo, Inc. | Unresolved — no canonical attribution shown | $27.60 | 14.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $21.54 | 11.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.19 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.69 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $129.36 | 1 | 2025 |
Source payment records
|
|||||
| CVAC ASPIRATION SYSTEM Normalized: cvac aspiration system |
Device | Calyxo, Inc. | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 577 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 539 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 468 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 132 |
| Omeprazole | Omeprazole | 353 | 117 |
| Losartan Potassium | Losartan Potassium | 322 | 104 |
| Furosemide | Furosemide | 317 | 106 |
| Lisinopril | Lisinopril | 316 | 105 |
| Metformin Hcl | Metformin Hcl | 292 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 285 | 99 |
| Montelukast Sodium | Montelukast Sodium | 245 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 88 |
| Gabapentin | Gabapentin | 232 | 57 |
| Meloxicam | Meloxicam | 225 | 65 |
| Trazodone Hcl | Trazodone Hcl | 197 | 59 |
| Eliquis | Apixaban | 195 | 51 |
| Glimepiride | Glimepiride | 191 | 65 |
| Potassium Chloride | Potassium Chloride | 188 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 74 |
| Buspirone Hcl | Buspirone Hcl | 177 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 50 |
| Carvedilol | Carvedilol | 160 | 46 |
| Sertraline Hcl | Sertraline Hcl | 159 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 133 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 49 |
| Alendronate Sodium | Alendronate Sodium | 125 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 31 |
| Ozempic | Semaglutide | 114 | 35 |
| Simvastatin | Simvastatin | 113 | 43 |
| Allopurinol | Allopurinol | 110 | 36 |
| Jardiance | Empagliflozin | 103 | 32 |
| Pregabalin | Pregabalin | 101 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 100 | 30 |
| Baclofen | Baclofen | 97 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 95 | 88 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 32 |
| Donepezil Hcl | Donepezil Hcl | 93 | 26 |
| Farxiga | Dapagliflozin Propanediol | 90 | 21 |
| Prednisone | Prednisone | 88 | 60 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 30 |
| Famotidine | Famotidine | 83 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 25 |
| Warfarin Sodium | Warfarin Sodium | 73 | 23 |
| Finasteride | Finasteride | 72 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 24 |
| Nifedipine Er | Nifedipine | 70 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 70 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 21 |
| Atenolol | Atenolol | 68 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 16 |
| Spironolactone | Spironolactone | 65 | 23 |
| Celecoxib | Celecoxib | 64 | 31 |
| Memantine Hcl | Memantine Hcl | 60 | 14 |
| Azithromycin | Azithromycin | 54 | 49 |
| Raloxifene Hcl | Raloxifene Hcl | 53 | 19 |
| Vascepa | Icosapent Ethyl | 52 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 21 |
| Fenofibrate | Fenofibrate | 49 | 14 |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Tramadol Hcl | Tramadol Hcl | 48 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 19 |
| Metformin Hcl Er | Metformin Hcl | 46 | 12 |
| Mirtazapine | Mirtazapine | 46 | 13 |
| Xarelto | Rivaroxaban | 45 | 13 |
| Bumetanide | Bumetanide | 41 | 14 |
| Clonidine Hcl | Clonidine Hcl | 41 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 15 |
| Topiramate | Topiramate | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 25 |
| Promethazine Hcl | Promethazine Hcl | 31 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 30 | 26 |
| Linzess | Linaclotide | 30 | 15 |
| Cilostazol | Cilostazol | 29 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Nystatin | Nystatin | 28 | 20 |
| Synthroid | Levothyroxine Sodium | 28 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Sucralfate | Sucralfate | 23 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Constulose | Lactulose | 22 | 14 |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Naproxen | Naproxen | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Alprazolam | Alprazolam | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.69 · 4 records | Bayer Healthcare Pharmaceuticals Inc. | CVAC ASPIRATION SYSTEM, ELIGARD, Kerendia, XYOSTED | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error